Major responses were observed in all tumor types including in anthracycline failures and in anthracycline-resistant cancers such as melanoma and cervical carcinoma, suggesting that inhibition of HDAC activity may chemosensitize tumor cells [269]. This evidence concerns the gene HDAC9 and neoplasm.